Since Horizon Pharma guided to a 50% year-over-year increase in Krystexxa sales in 2018 and peak sales of $750M, there has been "considerable debate as to whether or not the company can meet these high expectations," Cantor Fitzgerald analyst Louise Chen tells investors in a research note. After hosting calls with four rheumatologists that treat a large number of gout patients, the analyst says that while physicians believe Krystexxa is the safest and most-efficacious gout drug, they were not all convinced they would switch their patients over to Krystexxa. Chen sees division over Krystexxa adoption but keeps an Overweight rating on Horizon Pharma with a $17 price target.